Archives: News

  • News

    Luxembourg celebrates 10 years of progress in Parkinson’s research

    Learn more
  • News

    Competition for a new permanent artwork on Campus Belval

    Learn more
  • News

    Rejuvenating the brain with the help of a computational clock

    Learn more
  • News

    Using molecules produced by microbes to detect Parkinson’s disease early

    Learn more
  • News

    Digital health in Europe: Taking care of all and doing it right

    Learn more
  • News

    Prof. Michael Heneka receives the Tovi Comet-Walerstein Science Award

    Learn more
  • News

    Lessons learnt: Luxembourg’s COVID-19 management as a blueprint for pandemic preparedness

    Learn more
  • News

    International research on healthy aging, senescence and neurodegeneration at the Venusberg conference

    Learn more
  • News

    LCSB scientists reveal how Parkinson’s disease spreads using brain assembloids

    Learn more
  • News

    A public-private partnership to assess a novel drug candidate for Parkinson’s disease

    ACT-02 is a novel compound with disease-modifying potential. It inhibits the enzyme Prolyl Endopeptidase (PREP), a promising but previously overlooked target in Parkinson’s disease. This drug candidate has demonstrated properties to improve cognition while reducing motor symptoms, neuroinflammation and alpha-synuclein aggregation in preclinical models of brain disorders. The ACT-02 program is currently at an advanced…

    Learn more